Floatz logo

Treg Cells

Myeloproliferative Disorders

Stanford UniversityCell therapyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

79 Active assets in the Myeloproliferative Disorders cohort.

Asset / SponsorPhaseRating
Evomela
Center for International Blood and Marrow Transplant Research
Phase 2/3BBB
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2/3BB
Busulphan
Sawa Ito, MD
Phase 4BB
Fludarabine
Sawa Ito, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Treg Cells is also rated in:

chronic myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →
Chronic Myeloproliferative DiseaseDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →